DUBLIN--(BUSINESS WIRE)--The "Obsessive-Compulsive Disorder - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H1 2020, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.
Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.
The Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Report Coverage
- Obsessive-Compulsive Disorder - Overview
- Obsessive-Compulsive Disorder - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Obsessive-Compulsive Disorder - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Amorsa Therapeutics Inc
- Biogen Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Cannabis Science Inc
- Omeros Corp
- Rugen Therapeutics R&D (Shanghai) Co Ltd
- Seropeutics LLC
- Obsessive-Compulsive Disorder - Drug Profiles
- ADX-88178 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Obsessive-Compulsive Disorder - Dormant Projects
- Obsessive-Compulsive Disorder - Discontinued Products
- Obsessive-Compulsive Disorder - Product Development Milestones
- Featured News & Press Releases
- Sep 16, 2019: Omeros announces positive results from phase 1 study of its lead PDE7 inhibitor in development for addiction
- Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/d54uc6